JUBLPHARMA - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.0
| Stock Code | JUBLPHARMA | Market Cap | 15,435 Cr. | Current Price | 968 ₹ | High / Low | 1,250 ₹ |
| Book Value | 141 ₹ | Dividend Yield | 0.52 % | ROCE | 2.91 % | ROE | 1.04 % |
| Face Value | 1.00 ₹ | DMA 50 | 1,039 ₹ | DMA 200 | 1,058 ₹ | Chg in FII Hold | -0.60 % |
| Chg in DII Hold | 0.70 % | PAT Qtr | -48.0 Cr. | PAT Prev Qtr | 4.10 Cr. | RSI | 41.4 |
| MACD | -30.5 | Volume | 58,540 | Avg Vol 1Wk | 1,11,594 | Low price | 802 ₹ |
| High price | 1,250 ₹ | Debt to equity | 0.02 | 52w Index | 37.0 % | Qtr Profit Var | -436 % |
| EPS | 1.15 ₹ | Industry PE | 29.0 |
📉 Chart & Trend Analysis: JUBLPHARMA is trading at ₹968, below both its 50 DMA (₹1,039) and 200 DMA (₹1,058), signaling weak technical strength. RSI at 41.4 suggests the stock is nearing oversold territory. MACD at -30.5 confirms bearish momentum. Bollinger Bands show price leaning toward the lower band, indicating sustained selling pressure. Current volume (58K) is significantly below the 1-week average (1.11L), reflecting weak participation.
🔑 Momentum Signals: Short-term momentum is bearish with immediate support at ₹950 and major support at ₹802 (recent low). Resistance lies at ₹1,039–₹1,058 (DMA zone). Optimal entry zone: ₹950–₹970 for risk-managed traders. Exit zone: ₹1,039–₹1,058 if recovery occurs. Trend status: Reversing downward.
Positive ✅
- Low debt-to-equity (0.02) ensures strong financial stability.
- Dividend yield of 0.52% adds investor appeal.
- Book value of ₹141 provides margin-of-safety for long-term investors.
- DII holding increased (+0.70%), reflecting domestic institutional support.
Limitation ⚠️
- Stock trading below both 50 DMA and 200 DMA, confirming weak technical strength.
- ROCE (2.91%) and ROE (1.04%) are very modest, showing poor efficiency.
- Quarterly profit variation (-436%) highlights severe earnings volatility.
- Volume trend weaker than average, showing lack of strong buying support.
Company Negative News 📉
- FII holding decreased (-0.60%), showing reduced foreign investor confidence.
- Quarterly PAT dropped sharply to -₹48 Cr from ₹4.1 Cr, reflecting losses.
- Stock has fallen from 52-week high of ₹1,250 to ₹968, eroding sentiment.
Company Positive News 📊
- DII inflows (+0.70%) highlight domestic confidence in the company.
- Strong book value and low debt provide financial resilience despite weak earnings.
Industry 🌐
- Industry PE at 29.0 is unavailable for direct comparison as JUBLPHARMA currently has negative earnings, but peers may be more attractively valued.
- Pharma sector outlook remains positive with demand-driven growth opportunities, though valuations and earnings stability are critical.
Conclusion 📝
JUBLPHARMA is currently in a bearish reversal phase, trading below key moving averages with weak momentum indicators. While fundamentals show low debt and institutional support, declining profits and poor efficiency remain major concerns. Risk-tolerant traders may consider entries near ₹950–₹970 with exits around ₹1,039–₹1,058, while long-term investors should wait for confirmation of trend reversal above the 200 DMA.
Would you like me to also prepare a peer benchmarking overlay comparing JUBLPHARMA with pharma peers like Divi’s Lab, Cipla, and Sun Pharma to highlight relative strength and valuation?